Long-term follow-up of autologous hematopoietic stem cell transplantation for severe refractory Crohn's disease. 2011

Daniel W Hommes, and Marjolijn Duijvestein, and Zuzana Zelinkova, and Pieter C F Stokkers, and Maartje Holsbergen-de Ley, and Jaap Stoker, and Carlijn Voermans, and Marinus H J van Oers, and Marie José Kersten
Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands. d.w.hommes@lumc.nl

BACKGROUND Although new therapeutic strategies have been developed to control Crohn's disease, medical treatment for refractory cases is not able to prevent extensive and/or repeat surgery. Recently, several cases have been reported of successful remission induction in Crohn's disease patients by means of hematopoietic stem cell transplantation (HSCT). Here we report our long-term (4 to 6 years) outcome in three patients. METHODS Three patients (two male, one female) with active severe Crohn's disease were planned to undergo autologous HSCT. All patients were intolerant or refractory to conventional therapies, including anti-TNFα antibodies. Patients either refused surgery or surgery was considered not to be a feasible alternative due to the extensive disease involvement of the small intestine. METHODS Peripheral blood stem cells were mobilized using a single infusion of cyclophosphamide 4 g/m(2), followed on day 4 by subcutaneous injections with G-CSF 5 μg/kg twice daily until leukapheresis. CD34+ cells were isolated after leukapheresis by magnetic cell sorting. In two of the three patients a second round of stem cell mobilization using G-CSF only was required, either because of low yield or because of insufficient recovery after CD34 selection. Prior to transplantation, immune ablation was achieved using cyclophosphamide 50mg/kg/day (4 days), antithymocyte globulin 30 mg/kg/day (3 days) and prednisolone 500 mg (3 days). Endoscopy, barium small bowel enteroclysis and MRI enterography were performed. RESULTS All three patients successfully completed stem cell mobilization, and two of them subsequently underwent conditioning and autologous HSCT with CD34+ cell selection. Treatment was well tolerated, with acceptable toxicity. Now, 5 and 6 years post-transplantation, these patients are in remission under treatment. The third patient went into remission after mobilization and therefore she decided not to undergo conditioning and HSCT transplantation. After a successful pregnancy she relapsed two years later. Since then, she suffers from refractory Crohn's disease for which we are now reconsidering conditioning and transplantation. CONCLUSIONS Autologous HSCT appears to be safe and can be an alternative strategy for Crohn's disease patients with severe and therapy resistant disease.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D003424 Crohn Disease A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients. Colitis, Granulomatous,Enteritis, Granulomatous,Enteritis, Regional,Ileitis, Regional,Ileitis, Terminal,Ileocolitis,Crohn's Disease,Crohn's Enteritis,Inflammatory Bowel Disease 1,Regional Enteritis,Crohns Disease,Granulomatous Colitis,Granulomatous Enteritis,Regional Ileitides,Regional Ileitis,Terminal Ileitis
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D014182 Transplantation, Autologous Transplantation of an individual's own tissue from one site to another site. Autografting,Autologous Transplantation,Autotransplantation,Autograftings,Autologous Transplantations,Autotransplantations,Transplantations, Autologous

Related Publications

Daniel W Hommes, and Marjolijn Duijvestein, and Zuzana Zelinkova, and Pieter C F Stokkers, and Maartje Holsbergen-de Ley, and Jaap Stoker, and Carlijn Voermans, and Marinus H J van Oers, and Marie José Kersten
December 2010, Blood,
Daniel W Hommes, and Marjolijn Duijvestein, and Zuzana Zelinkova, and Pieter C F Stokkers, and Maartje Holsbergen-de Ley, and Jaap Stoker, and Carlijn Voermans, and Marinus H J van Oers, and Marie José Kersten
November 2018, Pediatric rheumatology online journal,
Daniel W Hommes, and Marjolijn Duijvestein, and Zuzana Zelinkova, and Pieter C F Stokkers, and Maartje Holsbergen-de Ley, and Jaap Stoker, and Carlijn Voermans, and Marinus H J van Oers, and Marie José Kersten
August 2003, Bone marrow transplantation,
Daniel W Hommes, and Marjolijn Duijvestein, and Zuzana Zelinkova, and Pieter C F Stokkers, and Maartje Holsbergen-de Ley, and Jaap Stoker, and Carlijn Voermans, and Marinus H J van Oers, and Marie José Kersten
January 2015, Revista brasileira de hematologia e hemoterapia,
Daniel W Hommes, and Marjolijn Duijvestein, and Zuzana Zelinkova, and Pieter C F Stokkers, and Maartje Holsbergen-de Ley, and Jaap Stoker, and Carlijn Voermans, and Marinus H J van Oers, and Marie José Kersten
January 2004, Blood,
Daniel W Hommes, and Marjolijn Duijvestein, and Zuzana Zelinkova, and Pieter C F Stokkers, and Maartje Holsbergen-de Ley, and Jaap Stoker, and Carlijn Voermans, and Marinus H J van Oers, and Marie José Kersten
March 2005, Gastroenterology,
Daniel W Hommes, and Marjolijn Duijvestein, and Zuzana Zelinkova, and Pieter C F Stokkers, and Maartje Holsbergen-de Ley, and Jaap Stoker, and Carlijn Voermans, and Marinus H J van Oers, and Marie José Kersten
August 2002, Autoimmunity reviews,
Daniel W Hommes, and Marjolijn Duijvestein, and Zuzana Zelinkova, and Pieter C F Stokkers, and Maartje Holsbergen-de Ley, and Jaap Stoker, and Carlijn Voermans, and Marinus H J van Oers, and Marie José Kersten
January 2018, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland,
Daniel W Hommes, and Marjolijn Duijvestein, and Zuzana Zelinkova, and Pieter C F Stokkers, and Maartje Holsbergen-de Ley, and Jaap Stoker, and Carlijn Voermans, and Marinus H J van Oers, and Marie José Kersten
May 2024, Multiple sclerosis (Houndmills, Basingstoke, England),
Daniel W Hommes, and Marjolijn Duijvestein, and Zuzana Zelinkova, and Pieter C F Stokkers, and Maartje Holsbergen-de Ley, and Jaap Stoker, and Carlijn Voermans, and Marinus H J van Oers, and Marie José Kersten
December 2008, La Revue du praticien,
Copied contents to your clipboard!